Highlights

• Dr Reddy’s launched generic Semaglutide Injection in the Canadian pharmaceutical market.
• Health Canada granted approval for generic Semaglutide Injection on April 28, 2026.
• Canada became the first G7 country approving generic Semaglutide Injection commercialization.

Dr. Reddy's Laboratories Limited (NSE:DRREDDY) shares traded lower on May 18, 2026, after the company announced the launch of its generic Semaglutide Injection in Canada following regulatory approval from Health Canada. Shares of NSE: DRREDDY were trading at INR 1,334.30, down 0.18% from the previous close of INR 1,336.70. The stock opened at INR 1,336.50 and touched an intraday low of INR 1,322 during the session.

The pharmaceutical company informed exchanges that it launched the product within days of receiving the Notice of Compliance from Health Canada on April 28, 2026. According to the company, Canada became the first G7 nation to grant market authorization for generic Semaglutide Injection.

Source: TradingView

Generic Semaglutide Launch Targets Type 2 Diabetes Market

Dr. Reddy’s stated that the generic Semaglutide Injection in Canada is indicated for once-weekly treatment of adults with type 2 diabetes mellitus to improve glycemic control alongside diet and exercise.

The product is supplied as a sterile solution for subcutaneous injection in pre-filled pen formats. It is available in 2 mg/pen and 4 mg/pen strengths, delivering Semaglutide at a concentration of 1.34 mg/ml. The 2 mg/pen version is designed for 0.25 mg or 0.5 mg doses, while the 4 mg/pen version delivers 1 mg doses per injection.

The company added that Semaglutide Injection can be used in combination with several diabetes treatment regimens including metformin, sulfonylureas, sodium-glucose cotransporter 2 inhibitors and basal insulin under prescribed conditions.

Company Highlights Expansion in GLP-1 Segment

Erez Israeli, Chief Executive Officer of Dr. Reddy’s, said the launch reflects the company’s readiness to serve Canadian patients following regulatory approval. He added that the launch builds on the company’s recent Semaglutide-related launch in India under the Obeda brand.

The company stated that GLP-1 therapies remain a focus area and that it is working to expand access across multiple international markets.

Dr. Reddy’s operates across APIs, generics, branded generics, biosimilars and OTC products, with major therapeutic focus areas including diabetology, oncology, gastrointestinal and cardiovascular segments.

Source: company filing

Market Activity Remains Range-Bound

Despite the product launch announcement, Dr. Reddy’s shares remained relatively range-bound during early trading. The stock traded between INR 1,322 and INR 1,341.90 during the session, while the volume-weighted average price stood at INR 1,330.84.

Investors may monitor future developments related to market penetration, competition in GLP-1 therapies and international regulatory approvals in additional geographies.

Key Risks

• Competitive GLP-1 market dynamics may impact product market share growth.
• Regulatory changes in international markets could affect commercialization timelines.
• Pricing pressure in generic pharmaceuticals may influence profitability margins.
• Currency fluctuations may impact overseas revenue realization and earnings.

Summary

Dr. Reddy’s Laboratories (NSE:DRREDDY) announced the launch of its generic Semaglutide Injection in Canada after receiving Health Canada approval in April 2026. The launch marks Canada as the first G7 country approving generic Semaglutide commercialization. The product targets adults with type 2 diabetes and is available in multiple pre-filled pen strengths. Dr. Reddy’s shares traded marginally lower following the announcement.

FAQs

Q: What did Dr. Reddy’s announce on May 15, 2026?
A: Dr. Reddy’s announced the launch of its generic Semaglutide Injection product in the Canadian pharmaceutical market.

Q: Why is Canada significant for Dr. Reddy’s Semaglutide launch?
A: Canada became the first G7 country granting approval for generic Semaglutide Injection commercialization and market access.

Q: What medical condition does generic Semaglutide Injection treat?
A: The injection is indicated for adults with type 2 diabetes mellitus to improve glycemic control.